Pharmacoeconomics Evaluation Of Rb-bFGF For Corneal Epithelial Defects After Launching A Drug To The Market

Objectives To evaluate the pharmacoeconomics of Beifushu eye drop (basic fibroblast growth factor, bFGF) for corneal epithelial defects. Methods The research collects 268 cases,of whom 137 accounting for 51.12 percent were treated BFGF and the remaining 131 were treated non-BFGF.theraphy use eye drops 1 to 2 drops 3 to 4 times daily for 5 days,and the control group theraphy is 1 to 2 drops 3 to 4 times daily for 8 days.A multi-central non-randomized controlled trial was conducted to collect the clinical data. Incremental cost-effectiveness analysis was used to evaluate the pharmacoeconomics effectiveness of the rb-bFGF. Budget impact analysis was conducted in order to make innovative drug reimbursement decision. Results The cure rate in treat group (rb-bFGF) is 94.16%, which is higher than the cure rate in control group (68.70%). Meanwhile, the cost was reduced by 1172 Yuan when 1% of the cure rate is increased. In addiction, rb-bFGF can reduce the total inpatient fee through improving the treat effectiveness and reducing the inpatient time. Conclusions The rb-bFGF is effective, safe and economic to treat corneal epithelial defects.